Renub Research

Global Epilepsy Drugs Market is expected US$ 9 Billion by 2025

Press release   •   Apr 12, 2019 05:01 EDT

For More Information:

https://www.renub.com/global-epilepsy-drugs-market-nd.php

Get Free Customization in This Report

Epilepsy is a neurological (central nervous system) disorder which affects the brain activity, causing seizures or involuntary episodes of unusual behavior, shaking a part or complete body and sometimes loss of awareness. The epilepsy patient may experience commotion of consciousness and movements along with sensory or psychiatric disorders. Anyone can develop epilepsy, irrespective of gender, age, and race, and can cause other health ailments also. It is the fourth most common cause of neurological disorder across the world and on an estimate; there are nearly 24 million people suffering from epilepsy worldwide, creating immense opportunity for the research and development of anti-epileptic drugs.

According to a report published by Renub Research, Global Epilepsy Drugs Market is anticipated to be more than USD 9 Billion opportunity for pharmaceutical companies by 2025. This report talks about the upcoming Epilepsy Drugs Market its future potential and drugs going through its clinical trial phases. The report also provides insights on the key factors that are driving the market growth and challenges which are restraining the market growth.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=epilepsy-drugs-market-p.php

People suffering from epilepsy may have more than one type of seizure and have other neurological disorder as well. Hence, to determine the treatment given, some of the common diagnostic tests for epilepsy patients include EEG (electroencephalogram) testing, family history, and clinical history. Epilepsy drugs (antiepileptic drugs) are medicines that are approved to treat epilepsy patients. Antiepileptic medicines (AEDs) are prescribed considering type and seriousness of seizure, the age of the patient and the part of the brain involved. Lyrica one of the leading antiepileptic brands, due to its efficacy, is widely recommended in treating epilepsy disorder. However, recently approved epilepsy drugs (Perampanel and Retigabine) are also driving the epilepsy drugs market as these drugs act through new molecular targets.

Epilepsy drugs are generally termed as anti-seizure or anticonvulsants drugs which are used for the symptomatic treatment of epilepsy. Epilepsy drugs act as a mood stabilizers and so it is used in the treatment of bipolar disorder or neuropathic pain. Though the cause of epilepsy is unclear, some of the major factors causing epilepsy include brain tumor, brain injury, stroke, and substance use disorder. Changing lifestyle, smoking, alcoholism and growing geriatric population are among the leading factors that are driving the epilepsy drugs market.

In addition, owing to the approvals of new drugs for epilepsy further expected to boost the growth of epilepsy drugs market over the forecast period. On the other hand, recent patent expiration of major brands offers massive opportunity for the generic drugs to come up in the market. It is expected that due to the recent and in future patent expiration of major brands, the epilepsy drugs market would become very much competitive and the prices of branded drugs would come down, which is expected to hinder the growth of Epilepsy Drugs Market in the near future.

Client can Purchase this Report in Sections from below link:

Access full Research: https://www.renub.com/epilepsy-drugs-market-p.php

Market Summary:

  • By Country: United States dominaties the epilepsy drugs market. US market share is expected to grow due to the better healthcare support system, growing awareness & increasing per capita healthcare expenditure. This report covers the market and market share of the United States, United Kingdom, France, Germany, Italy, Spain, India, China and Japan.
  • Drugs Category – By Generation: Second and Third generation drugs are having a big market share. This research report provides market and market share of First, Second, Third generation drugs.
  • By Drugs: Vimpat (Lacosamide) and Keppra (Levetiracetam) are holding big market share. Following drugs are covered in this report, Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex and Cenobamate (YKP3089).
  • By Companies: The report provides overview, initiatives and financial insights of Eisai Co. Ltd, UCB Inc., H. Lundbeck A/S and GW Pharmaceuticals Plc.

  • If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at info@renub.com


    Key Topics Covered :

    1. Introduction

    2. Research Methodology

    3. Executive Summary

    4. Global Epilepsy Drugs Market (2013 – 2025)

    5. Market Share – Global Epilepsy Drugs (2013 – 2025)

    6. Country - Global Epilepsy Drugs Market Analysis (2013 – 2025)

    7. By Drugs Category - Global Epilepsy Drugs Market Analysis (2013 – 2025)

    8. By Drugs - Global Epilepsy Drugs Market Analysis (2013 – 2025)

    9. Growth Drivers

    10. Challenges

    11. Eisai Co., Ltd.

    12. UCB Inc.

    13. H. Lundbeck A/S

    14. GW Pharmaceuticals Plc.


    Contact Us

    Email: info@renub.com

    Phone: +1-678-302-0700

    Web: www.renub.com

    Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

    Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today's ultra-competitive markets.